Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 6/20 | 0.47 |
| ▸ | KDR | P35968 | 5/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 9/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.41 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.39 |
| ▸ | DHODH | Q02127 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4678051 | 0.87 | KDR (0.44) | EGFRKDRMEN1KMT2APDGFRB | |
| SCHEMBL4680096 | 0.84 | EGFR (0.44) | EGFRKDREPHX2TRPA1DHODH | |
| SCHEMBL14283138 | 0.82 | EGFR (0.52) | EGFRKDRRAB9ATDP1ABCG2 | |
| SCHEMBL4682148 | 0.81 | BACE1 (0.46) | EGFRKDREPHX2MEN1RAB9A | |
| SCHEMBL4675893 | 0.79 | KIF11 (0.44) | EGFRKDREPHX2MEN1RAB9A | |
| SCHEMBL4677054 | 0.77 | EGFR (0.43) | EGFRKDREPHX2MEN1RAB9A | |
| SCHEMBL4675714 | 0.77 | EPHX2 (0.62) | EGFRKDREPHX2MEN1RAB9A | |
| SCHEMBL4674553 | 0.77 | EPHX2 (0.42) | EGFRKDREPHX2MEN1RAB9A | |
| SCHEMBL4678972 | 0.77 | EGFR (0.43) | EGFRKDREPHX2MEN1RAB9A | |
| SCHEMBL4676269 | 0.77 | TRPV1 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1625119-B1 | SUBSTITUTED-1-PHTHALAZINAMINES AS VR-1 ANTAGONISTS | MERCK SHARP & DOHME (GB) | 2008-07-23 | — | — | EP | disclosed |
| US-7329659-B2 | Substituted-1-phthalazinamines as vr-1 antagonists | MERCK SHARP & DOHME LIMITED (GB) | 2008-02-12 | — | — | US | disclosed |
| US-20060229307-A1 | Substituted-1-phthalazinamines as vr-1 antagonists | MERCK SHARP & DOHME LTD. (GB) | 2006-10-12 | — | — | US | disclosed |
| EP-1625119-A1 | SUBSTITUTED-1-PHTHALAZINAMINES AS VR-1 ANTAGONISTS | MERCK SHARP & DOHME LTD. (GB) | 2006-02-15 | — | — | EP | disclosed |
| WO-2004099177-A1 | SUBSTITUTED-1-PHTHALAZINAMINES AS VR-1 ANTAGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 2004-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229307-A1 | Substituted-1-phthalazinamines as vr-1 antagonists | TRPV1, ARRB1, AVPR1A | EGFR 2360/4885KDR 397/4885EPHX2 4276/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.